Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype–Phenotype Features—An Entity With an Increasing Incidence?
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2018.01.009
Abstract: Purpose To assess clinical characteristics of patients with metastatic pancreas ductal adenocarcinoma (PDAC) and brain metastases (BM), and to assess somatic and germ‐line molecular profiles where performed. Patients and Methods Patients with PDAC and BM… read more here.
Keywords: brain metastases; germ line; range months; months range ... See more keywords
Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-111551
Abstract: In light-chain (AL) amyloidosis, the depth of hematologic response has been shown to be associated with improved survival and organ responses. Bortezomib has been shown to be efficacious in achieving hematologic responses in AL amyloidosis.… read more here.
Keywords: months range; relapse; amyloidosis; bortezomib ... See more keywords
Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-118026
Abstract: Background With first-line imatinib (IM) therapy, approximately 50% of CP CML patients achieve undetectable molecular residual disease (UMRD). The recent several discontinuation clinical trials have demonstrated that IM discontinuation can be employed based on clinical… read more here.
Keywords: long term; months range; duration; kid study ... See more keywords
Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-127499
Abstract: Background: Treatment of Ph+ ALL has significantly improved since the addition of TKIs to chemotherapy, with improvement in complete molecular remission (CMR) and overall survival (OS) rates. However, the optimal duration of TKI is not… read more here.
Keywords: consultancy research; months range; research; research funding ... See more keywords
Outcomes of Cataract Surgery Following Treatment for Retinoblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Korean Journal of Ophthalmology : KJO"
DOI: 10.3341/kjo.2017.31.1.52
Abstract: Purpose To evaluate the long-term visual outcomes and complications of cataract surgery in eyes previously treated for retinoblastoma. Methods We reviewed the medical records of patients who underwent cataract extraction and intraocular lens implantation at… read more here.
Keywords: months range; treatment; retinoblastoma; outcomes cataract ... See more keywords
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.716467
Abstract: Introduction Melphalan, as a bifunctional alkylating agent has been shown to be selectively efficient in BRCA-deficient case reports of epithelial ovarian cancer (EOC). The clinical benefit of melphalan on unselected platinum-resistant EOC population and stratified… read more here.
Keywords: melphalan promising; platinum; months range; treatment ... See more keywords